StageZero Life Sciences Ltd. (SZLSF)

Market Cap	3.64M
Revenue (ttm)	2.88M
Net Income (ttm)	-12.53M
Shares Out	n/a
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Average Volume	1,289
Open	0.0240
Previous Close	0.0264
Day's Range	0.0240 - 0.0311
52-Week Range	0.0015 - 0.9999
Beta	0.31
RSI	66.32
Earnings Date	Aug 15, 2025

About StageZero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a...

• Industry: Diagnostics & Research
• Sector: Healthcare
• CEO: James Howard-Tripp
• Employees: 40
• Stock Exchange: OTCMKTS
• Ticker Symbol: SZLSF

Financial Performance

In 2022, StageZero Life Sciences's revenue was $3.80 million, a decrease of -25.12% compared to the previous year's $5.07 million. Losses were -$11.42 million, 52.5% more than in 2021.